Treatment of endocrine-resistent stage D carcinoma of prostate with a cisplatin derivative (DWA2114R): A pilot study

Y. Arai, T. Matsuda, T. Kamoto, T. Hashimura, K. Oishi, H. Takeuchi, O. Yoshida

Research output: Contribution to journalArticlepeer-review

Abstract

DWA2114R (DWA) is a new derivative of platin compounds. Eleven patients with rapidly progressive, endocrine-resistent stage D carcinoma of the prostate were treated with infusion of DWA (800 ~ 1,000 mg/m2) every 3 to 4 weeks. A partial objective response was observed in 3 of 11 patients (27%). This response lasted from 5 to 11 months with an average of 7.7 months. Six patients (55%) had a significant decrease or disappearance of bone pain and five became ambulatory and asymptomatic. Four patients (36%) showed no change, and four patients (36%) did not respond to the treatment and showed progression of their disease. There were no patients with severe leukopenia (< 1,000/mm3). No significant renal toxicity was observed in any of the patients and gastrointestinal toxicity was tolerable. DWA appears to be an effective drug available for the treatment of endocrine-resistent advanced carcinoma of the prostate.

Original languageEnglish
Pages (from-to)897-902
Number of pages6
JournalActa Urologica Japonica
Volume38
Issue number8
Publication statusPublished - 1992 Jan 1

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Treatment of endocrine-resistent stage D carcinoma of prostate with a cisplatin derivative (DWA2114R): A pilot study'. Together they form a unique fingerprint.

Cite this